Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence: ...
GlobalData on MSN1d
Lantheus acquires radiopharma CDMO Evergreen for up to $1bnThe deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Hosted on MSN1d
LNTH: Evergreen Acquisition Promotes Future InnovationLNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and ...
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...
Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage ...
Lantheus Holdings (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics, Inc. in an all-cash transaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback